XML 23 R10.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Revenue
3 Months Ended
Mar. 31, 2024
Revenue  
Revenue

3.           Revenue

The Company recognized $29,000 of revenue for the three months ended March 31, 2024, relating to recovery of clinical manufacturing costs associated with an investigator sponsored. There were no revenues recognized for the comparative period in 2023.